Idorsia announces
financial results for the
first half of 2020
Positive results in second
pivotal study with
daridorexant for
patients with
insomnia
There’s more to Idorsia
than meets the eye!
Read the interview with
our CEO & CSO to get to
the bottom of the story...
Our key assets have
the potential to
transform treatment in
the target indications...
We hope you find everything you need to understand how Idorsia intends to achieve its ambitious goals. If you need any further support please don't hesitate to reach out to us.
Shareprice
Stay informed
Idorsia offers an electronic ‘Stay informed’ service. You will get the news sent to you.
News
| 06 Aug 2020 | |
| 23 Jul 2020 | |
| 16 Jul 2020 | |
| 06 Jul 2020 |
Events
| Event | When |
| Nine-months 2020 Financial Results reporting* | October 22, 2020 |
| Full-Year 2020 Financial Results reporting* | February 4, 2021 |
| First Quarter 2021 Financial Results reporting | April 22, 2021 |
*We will be in a silent period for 10 days ahead of the financial reporting.
Financial information
The company reports on its financial performance on a quarterly basis starting its financial year on January 01. Read all the latest financial information from Idorsia, including our financial guidance and how the company is funded.
Our strategy
Find out more about the key priorities that management has set in order to develop Idorsia into one of Europe’s leading biopharmaceutical company.
Development pipeline
Idorsia has a diversified clinical development pipeline in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders, and orphan diseases.
Corporate reports
The company publishes a Half Year and Annual Report report summarizing its operational and financial performance, starting its financial year on January 01.
Stock information
The registered shares of Idorsia Ltd were listed on the SIX Swiss Exchange on June 16, 2017 (symbol: IDIA). Get all the latest information about our stock, interact with charting tools, and see what the covering analysts think about the company's future performance.
Contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations and Corporate Communications